Psyence Biomedical Ltd. Common Shares (PBM) — Strategic Asset Allocation Index
Psyence Biomedical Ltd. Common Shares (PBM) has a Strategic Asset Allocation Index of 43.6% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $5.17 Million) total $5.17 Million, measured against net assets of $11.87 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Psyence Biomedical Ltd. Common Shares's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Psyence Biomedical Ltd. Common Shares Strategic Asset Allocation Index (2025–2025)
This chart shows how Psyence Biomedical Ltd. Common Shares's Strategic Asset Allocation Index has evolved across 1 annual periods from 2025 to 2025. As of September 2025, the index stands at 43.6%, representing strategic assets of $5.17 Million against net assets of $11.87 Million USD. For live market cap and overall valuation, see PBM market cap.
Annual Strategic Asset Allocation Index for Psyence Biomedical Ltd. Common Shares (2025–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Psyence Biomedical Ltd. Common Shares from 2025 to 2025, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See what is Psyence Biomedical Ltd. Common Shares's book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 11.1% | $745.00K | $- | $745.00K | $6.72 Million | — |